Literature DB >> 16702993

Hypothalamic neuropeptide Y (NPY) and the attenuation of hyperphagia in streptozotocin diabetic rats treated with dopamine D1/D2 agonists.

Dong-Yih Kuo1.   

Abstract

1. Dopamine is an appetite suppressant, while neuropeptide Y (NPY), an appetite stimulant in the brain, is reported to be involved in anorectic action induced by a combined administration of D1/D2 agonists in normal rats. In diabetic rats, however, these factors have not been studied. 2. Rats (including normal, diabetic and insulin-treated diabetic rats) were given daily injections of saline or D1/D2 agonists for 6 days. Changes in food intake and hypothalamic NPY content of these rats were assessed and compared. 3. The D1/D2 agonist-induced anorectic responses were altered in diabetic rats compared to normal rats treated similarly. Both the anorectic response on the first day of dosing and the tolerant response on the subsequent days were attenuated. 4. This alteration was independent of the neuroendocrine disturbance on feeding behavior since the basic pattern of food intake during the time course of a 24-h day/night cycle was similar in normal and diabetic rats; the decrease of food intake following drug treatment was only shown at the initial interval of 0-6 h in both groups of rats. 5. However, this alteration coincided with changes in NPY content following D1/D2 coadministration. The replacement of insulin in diabetic rats could normalize both NPY content and D1/D2 agonist-induced anorexia. 6. It is demonstrated that the response of D1/D2 agonist-induced appetite suppression is attenuated in diabetic rats compared to normal rats and that elevated hypothalamic NPY content may contribute to this alteration.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16702993      PMCID: PMC1751870          DOI: 10.1038/sj.bjp.0706754

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  36 in total

1.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Authors:  P Chomczynski; N Sacchi
Journal:  Anal Biochem       Date:  1987-04       Impact factor: 3.365

2.  Decreased brain dopamine synthesis rate and increased [3H]spiroperidol binding in streptozotocin-diabetic rats.

Authors:  M E Trulson; C D Himmel
Journal:  J Neurochem       Date:  1983-05       Impact factor: 5.372

3.  Increased neuropeptide Y concentrations in specific hypothalamic regions of streptozocin-induced diabetic rats.

Authors:  G Williams; J S Gill; Y C Lee; H M Cardoso; B E Okpere; S R Bloom
Journal:  Diabetes       Date:  1989-03       Impact factor: 9.461

Review 4.  NPY and cohorts in regulating appetite, obesity and metabolic syndrome: beneficial effects of gene therapy.

Authors:  S P Kalra; P S Kalra
Journal:  Neuropeptides       Date:  2004-08       Impact factor: 3.286

5.  Further evidence for the mediation of both subtypes of dopamine D1/D2 receptors and cerebral neuropeptide Y (NPY) in amphetamine-induced appetite suppression.

Authors:  Dong-Yih Kuo
Journal:  Behav Brain Res       Date:  2003-12-17       Impact factor: 3.332

6.  Mapping of neuropeptide Y-like immunoreactivity in the feline hypothalamus and hypophysis.

Authors:  L Leger; Y Charnay; J M Danger; H Vaudry; G Pelletier; P M Dubois; M Jouvet
Journal:  J Comp Neurol       Date:  1987-01-08       Impact factor: 3.215

7.  Alterations in physiologic functions and in brain monoamine content in streptozocin-diabetic rats.

Authors:  P C Chu; M T Lin; L R Shian; S Y Leu
Journal:  Diabetes       Date:  1986-04       Impact factor: 9.461

8.  Radioimmunoassay of neuropeptide Y.

Authors:  J M Allen; J C Yeats; T E Adrian; S R Bloom
Journal:  Regul Pept       Date:  1984-01

Review 9.  Ontogeny of the hypothalamic neuropeptide Y system.

Authors:  Kevin L Grove; M Susan Smith
Journal:  Physiol Behav       Date:  2003-06

10.  Further studies on the interaction between bromocriptine and SKF38393 in reserpine and alpha methyl-para-tyrosine-treated mice.

Authors:  D M Jackson; S B Ross; M Hashizume
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

View more
  6 in total

1.  Common Phenotype in Patients with Both Food and Substance Dependence: Case Reports.

Authors:  Hb Campbell; M Oscar-Berman; J Giordano; Tg Beley; D Barh; Bw Downs; K Blum
Journal:  J Genet Syndr Gene Ther       Date:  2013-02-06

2.  Knockdown of the transcript of ERK in the brain modulates hypothalamic neuropeptide-mediated appetite control in amphetamine-treated rats.

Authors:  Ching-Han Yu; Yih-Shou Hsieh; Pei-Ni Chen; Jeng-Rung Chen; Dong-Yih Kuo
Journal:  Br J Pharmacol       Date:  2018-01-11       Impact factor: 8.739

3.  Involvement of hypothalamic PI3K-STAT3 signalling in regulating appetite suppression mediated by amphetamine.

Authors:  Shu-Chen Chu; Pei-Ni Chen; Yih-Shou Hsieh; Ching-Han Yu; Meng-Hsuan Lin; Yan-Han Lin; Dong-Yih Kuo
Journal:  Br J Pharmacol       Date:  2014-07       Impact factor: 8.739

4.  Alterations to melanocortinergic, GABAergic and cannabinoid neurotransmission associated with olanzapine-induced weight gain.

Authors:  Katrina Weston-Green; Xu-Feng Huang; Chao Deng
Journal:  PLoS One       Date:  2012-03-16       Impact factor: 3.240

Review 5.  Brain signaling systems in the Type 2 diabetes and metabolic syndrome: promising target to treat and prevent these diseases.

Authors:  Alexander O Shpakov; Kira V Derkach; Lev M Berstein
Journal:  Future Sci OA       Date:  2015-11-01

Review 6.  The functional state of hormone-sensitive adenylyl cyclase signaling system in diabetes mellitus.

Authors:  Alexander O Shpakov; Kira V Derkach
Journal:  J Signal Transduct       Date:  2013-09-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.